Although ARID1A exerts cancer initiation function in certain contexts, particularly in multiple in vivo liver cancer models where ARID1A clearly presents tumor-promoting functions, the majority of data recently indicate that mutations in ARID1A usually lead to its loss of function, which makes ARID1A to be reconsidered as a tumor suppressor in a broader variety of cancers (12, 30, 31). This evidence concerns the gene ARID1A and cancer.